Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

BLISS GVS PHARMA LTD. - 506197 - Intimation Of Book Closure In Accordance With Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 According to section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Register of Members and Share Transfer Books of the Company will remain closed from Friday, July 19, 2024 to Thursday, July 25, 2024 (both days inclusive) for taking on record of the members of the Company for the purpose of holding 39th Annual General Meeting of the Company which will be held on Thursday. July 25, 2024, for the financial year ended March 31, 2024 and payment of Final Dividend for the financial year ended March 31, 2024.
02-05-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Corporate Action-Board approves Dividend

 Recommended Final Dividend of 50% i.e. 0.50 Paisa per equity share on the face value of Rs. 1/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders in the forthcoming 39th Annual General Meeting of the Company.
02-05-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Corporate Action-Board to consider Dividend

 Recommended Final Dividend of 50% i.e. 50 Paisa per equity share on the face value of Rs. 1/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders in the forthcoming 39th Annual General Meeting of the Company.
02-05-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2024

 Please find attached herewith Outcome of the Board Meeting held on May 02, 2024.
02-05-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Board Meeting Outcome for Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2024 And Final Dividend For The Financial Year 2023-2024

 We would like to inform you that, the Board Meeting of the Company was held today i.e. Thursday, May 02, 2024 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters amongst others as attached.
02-05-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Please find enclosed herewith the yearly compliance certificate issued by the Company Secretary in Practice as per Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2024.
29-04-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for For Considering Financial Results For The Quarter And Financial Year Ending March 31, 2024

 BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 ,inter alia, to consider and approve a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2024, along with the Statement of Assets and Liabilities, Cash Flow Statement and take note of the Audit Report with modified opinion, if any, thereon; b) To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31, 2024; and c) To discuss and recommend the Final Dividend, if any, for the financial year ended March 31, 2024.
25-04-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Compliance Certificate Under Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Period April 01, 2023 To March 31, 2024

 Please find enclosed herewith the Compliance Certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the period April 01, 2023 to March 31, 2024.
10-04-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed herewith a certificate received from Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2024.
10-04-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Closure of Trading Window

 This is to inform you that pursuant to the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any stautory modification(s) or re-enactment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited ("the Company")shall remain closed for all the Deignated Persons and their immediate relatives of the Company with effect from April 01, 2024, till completion of 48 hours after the announcement of the Audited Financial Results for the financial year ended March 31, 2024.
29-03-2024
Next Page
Close

Let's Open Free Demat Account